Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
DRUG IMCGP100-202 -A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Chandra, Sunandana
(PD/PI)
Medicine, Hematology Oncology Division
Project
:
Research project
Overview
Project Details
Status
Finished
Effective start/end date
11/14/17
→
11/14/20
Funding
DrugDev Inc.
(IMCGP100-202)
Immunocore Limited
(IMCGP100-202)
View all
View less